Abstract
Background: This study was performed to determine the efficacy of gemcitabine and oxaliplatin in patients with advanced or metastatic pancreatic adenocarcinoma (ACA). Patients and methods: Pancreatic ACA patients with previously untreated advanced or metastatic disease were enrolled in a phase II study of gemcitabine and oxaliplatin. Oxaliplatin was given i.v. on day 1 and gemcitabine i.v. on days 1 and 8 of a 3-week cycle. The primary end point of the trial was 6-month survival. Secondary end points included response rate, overall survival, median time to progression and toxicity. Results: A total of 47 patients were enrolled, 46 of whom were evaluable. Of those patients assessed for the primary end point 50% lived for ≥6 months. The median time to progression was 4.53 months. Five confirmed responses were seen with a median duration of response of 2.7 months. Overall, the treatment was well tolerated. However, one patient died as a result of treatment-related hemolytic uremic syndrome. Conclusions: Gemcitabine and oxaliplatin, at doses of 1000 mg/m 2 and 100 mg/m2, respectively, showed moderate activity in patients with pancreatic ACA. Based on the results of this study further evaluation of this combination is warranted.
Original language | English (US) |
---|---|
Pages (from-to) | 580-585 |
Number of pages | 6 |
Journal | Annals of Oncology |
Volume | 14 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2003 |
Keywords
- Gemcitabine
- Oxaliplatin
- Pancreatic cancer
- Phase II trial
ASJC Scopus subject areas
- Hematology
- Oncology